Evidence map›Paper›PMID 40500714›Full record

Trial reportJournal of neuroengineering and rehabilitation2025

Combining immersive exergaming with physiotherapy in a specialized intensive Parkinson's disease rehabilitation program: a randomized controlled trial.

Daniela Pimenta Silva, Raquel Bouça-Machado, Filipa Pona-Ferreira, Teresa Lobo, Ricardo Cacho, Rebekka Anker, John W Krakauer, Joaquim J Ferreira

Registry-linked trialAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of neuroengineering and rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04699617 (The Feasibility and Efficacy of an Immersive Virtual Reality Software in Parkinson's Disease Patients), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04699617 nacompletednot on this map

The Feasibility and Efficacy of an Immersive Virtual Reality Software in Parkinson's Disease Patients

TypeinterventionalSponsorCampus Neurológico SéniorRan2020 to 2022Enrolled30ConditionsParkinson DiseaseArmsDolphin 2.0
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniela Pimenta SilvaCentro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
Raquel Bouça-MachadoLaboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, Lisbon, 1649-028, Portugal.
Filipa Pona-FerreiraCNS - Campus Neurológico, Torres Vedras, Portugal.
Teresa LoboCNS - Campus Neurológico, Torres Vedras, Portugal.
Ricardo CachoCNS - Campus Neurológico, Torres Vedras, Portugal.
Rebekka AnkerMindMaze SA, Lausanne, Switzerland.
John W KrakauerJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Joaquim J FerreiraLaboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, Lisbon, 1649-028, Portugal. jferreira@medicina.ulisboa.pt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExergaming is a new technology for implementing innovative rehabilitation interventions for neurological conditions. Our aim was to evaluate the feasibility, safety and efficacy of a novel exergaming experience called neuroanimation, in the form of MindPod

methodsMindPod Dolphin provides a 2D oceanic environment where patients make high-amplitude 3D arm movements controlling an animated dolphin. We conducted a rater-blinded, randomized-controlled trial. Eligible people with PD were assigned into two groups: MindPod Dolphin over 12-weeks combined with physiotherapy (COM) or sequentially after 6-weeks of physiotherapy alone (SEQ). Sessions occurred three times/week. Assessments occurred at baseline, 6-week, 12-week, and 4-week post-intervention. The primary outcome was change from baseline to 6-week in the Timed Up and Go (TUG) test. Secondary outcomes were change, from baseline to each evaluation timepoint, in several motor, cognitive and quality of life measures. Participants' safety was assessed. Adherence, system usability and participants' satisfaction were used as measures of feasibility.

resultsThirty individuals were recruited. Baseline characteristics were similar between groups. Our primary outcome (change in TUG from baseline to 6-week) did not significantly differ between groups [median TUG change in COM = 0.243 [-1.873, 1.176] vs. SEQ=-0.016 [-0.810, 0.350], estimated difference = 0.002 (95%CI -1.103; 1.273); p = 0.983]. Both groups improved in motor and cognitive measures with a trend favoring COM. When compared to SEQ, COM improved significantly in TUG cognitive from baseline to 16-week (p = 0.048). A main effect of time was observed for TUG cognitive in COM, and mini-BEST in SEQ. Adverse events (n = 309) were mostly mild (55%). Overall, 20 participants (67%) adhered to the study protocol, with the COM being more compliant than the SEQ group. MindPod Dolphin was considered easy to use and over 80% of participants were at least moderately satisfied with it as an intervention.

conclusionsNeuroanimation-based exergaming in PD was feasible, safe and effective in improving multiple secondary measures. The advantages of the exergame became evident at 12-weeks and beyond, suggesting that it had cumulative and delayed beneficial effects on cognitive and motor outcomes when added to a lead-in phase of intense physiotherapy.

trial registrationClinicalTrials.gov registration: NCT04699617.

Indexed as

Exercise TherapyParkinson DiseasePhysical Therapy ModalitiesVideo GamesAgedFeasibility StudiesFemaleHumansMaleMiddle AgedQuality of LifeSingle-Blind MethodTreatment OutcomeExercise therapyExergamingNeurological rehabilitationParkinson diseaseVirtual reality

Identifiers

PMID40500714
PMCPMC12153140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.